FDA issues draft guidance on marketing submissions for AI-enabled medical devices
The Food and Drug Administration issued draft guidance Jan. 6 on marketing submissions and lifecycle management for artificial intelligence-enabled devices. The guidance clarifies differences in terminology between the FDA and the AI device manufacturers and software developers. In addition, it provides recommendations on information needed throughout a product's life cycle for regulation of safety and efficacy.
Related News Articles
Headline
The AHA has released a fact sheet explaining how artificial intelligence tools help alleviate administrative burden for providers, particularly in areas such…
Headline
The Food and Drug Administration is seeking public feedback on a discussion paper released today on potential regulatory approaches for generative artificial…
Headline
The AHA Aug. 13 responded to a Food and Drug Administration request for input on the risks and benefits to health and safety associated with non-device…
Headline
The Common Health Coalition announced Aug. 13 that it will receive $100 million in funding from the OpenAI Foundation for a new initiative using artificial…
Headline
The AHA’s American Organization for Nursing Leadership will host a webinar Aug. 5 at noon ET on how nurse leaders can guide ambient documentation from pilot…
Headline
In this conversation, Ajay Gupta, board vice chair for Trinity Health Mid-Atlantic, explains how trustees can confidently guide artificial intelligence…